QL1706

Clinical trials for QL1706 explained in plain language.

Never miss a new study

Get alerted when new QL1706 trials appear

Sign up with your email to follow new studies for QL1706, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 3

New Triple-Threat attack on tough liver cancer

Disease control Recruiting now

This study is testing a three-part treatment for advanced liver cancer that has spread into a major vein in the liver. The treatment combines immunotherapy (QL1706), a drug that blocks tumor blood supply (bevacizumab), and chemotherapy delivered directly into the liver's artery. …

Matched conditions: QL1706

Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control

Last updated Apr 13, 2026 20:18 UTC

QL1706

Get alerted when new QL1706 trials appear

New Triple-Threat attack on tough liver cancer